AI-generated from publicly available materials.Agilent Technologies has announced its acquisition of digital pathology firm Proscia for $240 million, with potential additional payments based on future performance.
This acquisition grants Agilent access to Proscia's Concentriq software platform, which serves as a pivotal tool for digital pathology, aiding clinical and life sciences entities in the U.S. and Europe. The platform is currently utilized by over 4,000 laboratories, hospitals, and pharmaceutical companies to streamline the management of images, data, and workflows. Unlike many pathology software solutions that focus narrowly on specific diseases, Concentriq is designed for a wider application across various clinical diagnostics and life sciences research, incorporating third-party AI functionalities.
The acquisition follows a multi-year distribution agreement between Agilent and Proscia established in September 2022, aimed at creating a comprehensive digital diagnostic pathology system. Agilent's President and CEO, Padraig McDonnell, emphasized that this move significantly enhances the company's footprint in the rapidly advancing digital pathology market, which is becoming essential for data generation and analysis in biopharmaceutical research and clinical diagnostics.
This strategic acquisition positions Agilent to better support laboratories and biopharma clients in managing and extracting valuable insights from pathology data, marking a significant step towards integrating AI-driven analysis within routine clinical practices and precision medicine.